Fosgemcitabine
Trade name: acelarin
Small moleculeexperimental
Clinical trial activity
2 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
1
Phase 4
0
Earliest trial started Dec 31, 2015 (NCT03610100)
Timeline
Indications
Mechanism of action
- DNAINHIBITOR
DNA inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- acelarin
- acelarin
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02351765 | Phase 1 | Jan 1, 2016 | The Christie NHS Foundation Trust |
| NCT03610100 | Phase 2/Phase 3 (Phase 3) | Dec 31, 2015 | Cancer Research UK, University of Liverpool |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Cancer Research UK | Academic/Hospital | 1 | 0 | 1 | 2015 |
| The Christie NHS Foundation Trust | Academic/Hospital | 1 | 1 | 1 | 2016 |
| University of Liverpool | Academic/Hospital | 1 | 1 | 1 | 2015 |
3 organizations
Page 1 / 1